Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: A comprehensive analysis

Innate Immunity

Volumn 16, Issue 2, 2010, Pages 93-103

  Vamadevan, Arunan S ^a   Fukata, Masayuki ^a   Arnold, Elizabeth T ^b   Thomas, Lisa S ^c   Hsu, David ^d   Abreu, Maria T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Histone de acetylation; Intestinal epithelial cells; Lipopolysaccharide; MD 2; Methylation; Toll like receptor 4 (TLR4)

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN MD 2; TOLL LIKE RECEPTOR 4;

ARTICLE; BACTERIAL IMMUNITY; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; CELL STRAIN HT29; CONTROLLED STUDY; DOWN REGULATION; ENTERITIS; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; MUCOSAL IMMUNITY; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

AZACITIDINE; CACO-2 CELLS; CELL POLARITY; DNA METHYLATION; HUMANS; HYDROXAMIC ACIDS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TOLL-LIKE RECEPTOR 4; TRANSCRIPTIONAL ACTIVATION;

NEGIBACTERIA;

EID: 77952381089     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909339231     Document Type: Article

References (62)

1. Ismail A, Hooper L. Epithelial cells and their neighbors. IV. Bacterial contributions to intestinal epithelial barrier integrity. Am J Physiol 2005; 289: G779-G784. (Pubitemid 41532569)
2. Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder, Inflamm Bowel Dis 2001; 7: 136-145. (Pubitemid 32998502)
3. Hu L, Hickey T. Campylobacter jejuni induces secretion of proinflammatory chemokines from, human intestinal epithelial cells. Infect Immun 2005; 73: 4437-4440. (Pubitemid 40923196)
4. Hecht G. Innate mechanisms of epithelial host defense: spotlight on intestine. Am J Physiol 1.999; 277: C351-C358.
5. Gribar SC, Richardson WM, Sodhi CP, Hackam DJ. No longer an innocent bystander: epithelial Toll-like receptor signaling in the development of mucosal inflammation. Mol Med 2008; 14: 645-659.
6. Veltkamp C, Tonkonogy S, De Jong Y et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology 2001; 120: 900-913. (Pubitemid 32193187)
7. MacDonald T, Pettersson S. Bacterial, regulation of intestinal immune responses. Inflamm Bowel Dis 2000; 6: 116-122.
8. Rath HC. Role of commensal bacteria in chronic experimental colitis: lessons from, the HLA-B27 transgenic rat. Pathobiology 2002; 70: 131-138.
9. Zenewicz L, Yancopoulos G, Valenzuela D et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-957.
10. Gunter M, Stolzenberg-Solomon R, Cross A et al. A prospective study of serum C-reactive protein and colorectal, cancer risk in men. Cancer Res 2006; 66: 2483-2487. (Pubitemid 43294965)
11. Itzkowitz S, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol 2004; 287: G7-G17. (Pubitemid 38802113)
12. Jess T, Loftus EV, Velayos FS et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-836. (Pubitemid 46496613)
13. Engle SJ, Ormsby 1, Pawlowski. S et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002; 62: 6362-6366.
14. Kado S, Uchida K, Funabashi H et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 doubleknockout mice. Cancer Res 2001; 61: 2395-2398. (Pubitemid 32685812)
15. Cario E, Podolsky D. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7017. (Pubitemid 32463415)
16. Hausmann M, Kiessling S, Mestermann S et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002; 122: 1987-2000. (Pubitemid 34651441)
17. Fukata M, Michelsen K, Eri R et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol 2005; 288: G1055-G1065. (Pubitemid 40563149)
18. Fukata M, Chen A, Vamadevan A et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133: 1869-1881.
19. Abreu MT, Vora P, Faure E et al. Decreased expression of Tolllike receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001; 167: 1609-1616. (Pubitemid 32703162)
20. Abreu MT, Arnold ET, Thomas LS et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002; 277: 20431-20437.
21. Aderem A, Ulevitch R. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-787.
22. Ulevitch R, Tobias P. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-457.
23. Medzhitov R, Janeway CJ. Innate immunity. N Engl J Med 2000; 343: 338-344.
24. Teghanemt A, Widstrom R, Gioannini T, Weiss J. Isolation of monomeric and dimeric secreted MD-2. Endotoxin.sCD14 and Toll-like receptor 4 ectodomain selectively react with the monomeric form, of secreted MD-2. J Biol Chem 2008; 283: 21881-21889.
25. Mollnes TE, Christiansen D, Brekke OL, Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Curr Top Complement II 2008; 632: 253-263.
26. Shimazu R, Akashi. S, Ogata H et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-1782. (Pubitemid 29272694)
27. Beutler B. TLR4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000; 12: 20-26. (Pubitemid 30093446)
28. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-10692. (Pubitemid 129528264)
29. Lien E, Means TK, Heine H et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497-504. (Pubitemid 30127250)
30. Dziarski R, Wang Q, Miyake K, Kirschning C, Gupta D. MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol 2001; 166: 1938-1944. (Pubitemid 32114681)
31. Reimer T, Brcic M, Schweizer M, Jungi T. Poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J Leukoc Biol 2008; 83: 1249-1257. (Pubitemid 351960357)
32. Suzuki M, Hisamatsu, Podolsky D. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated upregulation of LPS uptake and expression of the intracellular Tolllike receptor 4-MD-2 complex. Infect Immun 2003; 71; 3503-3511. (Pubitemid 36637579)
33. Nagai Y, Akashi S, Nagafuku M et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-672. (Pubitemid 34752476)
34. Mancek M, Pristovsek P, Jerala R. Identification of LPS-binding peptide fragment of MD-2, a Toll-receptor accessory protein. Biochem Biophys Res Commun 2002; 292: 880-885. (Pubitemid 34687286)
35. Lenoir C, Sapin C, Broquet A et al. MD-2 controls bacterial lipopolysaccharide hyporesponsiveness in human intestinal, epithelial cells. Life Sci 2008; 82: 519-528.
36. Visintin A, Latz E, Monks B, Espevik T, Golenbock D. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction, J Biol Chem 2003; 278: 48313-48320. (Pubitemid 37523286)
37. Hyakushima N, Mitsuzawa H, Nishitani C et al. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4mediated signaling. J Immunol 2004; 173: 6949-6954. (Pubitemid 39541083)
38. Akash IS, Saitoh. S, Wakabayashi Y et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198: 1035-1042. (Pubitemid 37248619)
39. Jain V, Halle A, Halmen K et al. Phagocytosis and intracellular killing of MD-2 opsonized Gram-negative bacteria depend on TLR4 signaling. Blood 2008; 111: 4637-4645.
40. Visintin A, Iliev DB, Monks BG, Halmen KA, Golenbock DT. MD-2. Immunobiology 2006; 211: 437-447.
41. Kobayashi M, Saitoh S, Tanimura N et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 2006; 176: 6211-6218.
42. Park B, Song D, Kim. H et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195.
43. Abreu M, Palladino A, Arnold E, Kwon R, McRoberts J. Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells. Gastroenterology 2000; 119: 1524-1536. (Pubitemid 32198678)
44. Dharmsathaphorn K, McRoberts J, Mandel. K, Tisdale L, Masui H. A human colonic tumor cell line that maintains vectorial electrolyte transport. Am J Physiol 1984; 246: G204-G208. (Pubitemid 14147681)
45. Ades E, Candal F, Swerlick R et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690. (Pubitemid 23002027)
46. Zhang F, Kirschning C, Mancinelli R et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal, endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274: 7611-7614. (Pubitemid 129518142)
47. Faure E, Equils O, Sieling PA et al. Bacterial lipopolysaccharide activates NF-kappaB through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000; 275: 11058-11063. (Pubitemid 30212746)
48. McIntire F, Sievert H, Barlow G, Finley R, Lee A. Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry 1967; 6: 2363-2372.
49. Qureshi N, Takayama K, Sievert T et al. Novel method for the purification and characterization of lipopolysaccharide from. Escherichia coli D31m3. Prog Clin Biol Res 1995; 392: 151-160.
50. Hirschfeld M, Ma Y, Weis J, Vogel S, Weis J. Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 2000; 165: 618-622. (Pubitemid 30484724)
51. Hogan M, Vogel S. Inhibition of macrophage tumoricidal activity by glucocorticoids. J Immunol 1988; 140: 513-519. (Pubitemid 18056776)
52. Hogan M, Vogel S. Lipid A-associated proteins provide an alternate 'second signal' in the activation of recombinant interferon-gamma-primed, C3H/HeJ macrophages to a fully tumoricidal state. J Immunol 1987; 139: 3697-3702.
53. Van den Brande J, Koehler T, Zelinkova Z et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007; 56: 509-517. (Pubitemid 46580507)
54. Yamada N, Nishida Y, Tsutsumida H et al. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer 2009; 100: 344-351.
55. Bird A. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-213. (Pubitemid 16016411)
56. Sterner D, Berger S. Acetylation of histones and transcriptionrelated factors. Microbiol Mol Biol Rev 2000; 64: 435-459.
57. Roth S, Denu J, Allis C. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
58. Khochbin S, Kao H. Histone deacetylase complexes: functional entities or molecular reservoirs. FEBS Lett 2001; 494: 141-144. (Pubitemid 32322671)
59. Otte JM, Cario E, Podolsky DK, Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial, ligands in intestinal epithelial cells. Gastroenterology 2004; 126: 1054-1070. (Pubitemid 38451177)
60. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167: 1882-1885. (Pubitemid 32747491)
61. Eaves-Pyles T, Murthy K, Liaudet L et al. Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J Immunol 2001; 166: 1248-1260. (Pubitemid 32060286)
62. Abreu M, Thomas L, Arnold E et al. TLR signaling at the intestinal epithelial interface. J Endotoxin Res 2003; 9: 322-330.